N N Sarkar1. 1. Department of Reproductive Biology, All India Institute of Medical Sciences, New Delhi.
Abstract
OBJECTIVES: The aim of this study is to review the development of NuvaRing over the past decade to illustrate its use-effectiveness and acceptance as an alternative contraceptive option for women. METHODS: The data were extracted from the literature using computerised MEDLINE system. NuvaRing is a new combined hormonal contraceptive vaginal ring made of ethylene-vinyl-acetate copolymer, releasing 120 microg etonorgestrel and 15 microg ethinyloestradiol per day. This ring is inserted on any day from day 1 to day 5 of a menstrual cycle for 21 days, thereafter removed for 7 days ring-free period and discarded. RESULTS: Complete inhibition of ovulation is observed during treatment with this device. Clinical exposure to NuvaRing for 1786 women-years has resulted in 21 pregnancies, giving a Pearl Index of 1.18. Withdrawal bleeding (4.7-5.3 days) is regular (97-99% of cycles) with rare incidence of irregular bleeding (2.6-6.4%). The cycle control is good with the use of this combined contraceptive vaginal ring. NuvaRing is well tolerated and accepted by women as compared to oral pill. CONCLUSIONS: NuvaRing is an effective vaginal contraceptive option for women. However, further study is needed for monitoring its long-term effectiveness and impact on patient's quality of life since the NuvaRing is marketed in many countries.
OBJECTIVES: The aim of this study is to review the development of NuvaRing over the past decade to illustrate its use-effectiveness and acceptance as an alternative contraceptive option for women. METHODS: The data were extracted from the literature using computerised MEDLINE system. NuvaRing is a new combined hormonal contraceptive vaginal ring made of ethylene-vinyl-acetate copolymer, releasing 120 microg etonorgestrel and 15 microg ethinyloestradiol per day. This ring is inserted on any day from day 1 to day 5 of a menstrual cycle for 21 days, thereafter removed for 7 days ring-free period and discarded. RESULTS: Complete inhibition of ovulation is observed during treatment with this device. Clinical exposure to NuvaRing for 1786 women-years has resulted in 21 pregnancies, giving a Pearl Index of 1.18. Withdrawal bleeding (4.7-5.3 days) is regular (97-99% of cycles) with rare incidence of irregular bleeding (2.6-6.4%). The cycle control is good with the use of this combined contraceptive vaginal ring. NuvaRing is well tolerated and accepted by women as compared to oral pill. CONCLUSIONS: NuvaRing is an effective vaginal contraceptive option for women. However, further study is needed for monitoring its long-term effectiveness and impact on patient's quality of life since the NuvaRing is marketed in many countries.
Authors: Manpreet Kaur; Kavita M Gupta; Azadeh E Poursaid; Prasoona Karra; Alamelu Mahalingam; Hyder A Aliyar; Patrick F Kiser Journal: Drug Deliv Transl Res Date: 2011-06 Impact factor: 4.617
Authors: Nick X Wang; Scott F Sieg; Michael M Lederman; Robin E Offord; Oliver Hartley; Horst A von Recum Journal: Mol Pharm Date: 2013-08-26 Impact factor: 4.939
Authors: Pedro M M Mesquita; Rachna Rastogi; Theodore J Segarra; Ryan S Teller; N Merna Torres; Ashley M Huber; Patrick F Kiser; Betsy C Herold Journal: J Antimicrob Chemother Date: 2012-03-30 Impact factor: 5.790
Authors: Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2012-09-24 Impact factor: 5.191